Abstract:The effect of inhaled corticosteroid on bone mineral density (BMD) was investigated in 44 asthmatic patients after median treatment duration of 6.5 years. Compared with controls, BMD decreased only in patients aged <50 years in both the spine (11.3 %, p = 0.013) and hip (8.8 %, p = 0.044), whereas in patients ≥50 years BMD did not decrease significantly.IntroductionThe results of studies which addressed the impact of inhaled corticosteroid (ICS) therapy on BMD of patients with asthma are conflicting. This case–control study aimed to compare BMD status in ICS user with asthma with healthy controls according to age.MethodsBMD at the lumbar spine (LS), femoral neck (FN) was measured by dual energy X-ray absorptiometry (DEXA). Patients and controls were compared according to BMD gr/cm2, BMD T-score, BMD Z-score, frequency of osteoporosis (defined as BMD T-score ≤−2.5), and frequency of patients with BMD Z-score <−1 at LS and FN with regard to age <50 and ≥50 years old.ResultsForty-four ICS user patients (females 63.6 %) with median treatment duration of 6.5 years and 50 controls (females, 69.4 %) with respective mean age of 49.2 ± 9.5 and 47.4 ± 10.5 years (p = 0.38 and p = 0.35) entered the study. Overall LS-BMD and FN-BMD gr/cm2 in total patients were lower than in controls by 6 % (p = 0.065) and 5.9 % (p = 0.09), respectively. In patients <50 years, mean LS-BMD gr/cm2 was lower than controls by 11.3 % (p = 0.013) and FN-BMD by 8.8 % (p = 0.044). Mean BMD T-score and BMD Z-score in both measurement sites were also lower than controls (p = 0.013 and 0.01, respectively. Frequency of osteoporosis did not differ but frequency of patients with BMD Z-score <−1 was significantly higher in patients (odds ratio (OR) = 6.57 95 % CI, 1.8–23.9, p = 0.004). In age group ≥50 years old, reduction of BMD in both measurement sites did not reach to a significant level.ConclusionThis study indicates that BMD reduction in ICS user with asthma is dependent on age and appears that younger patients are at greater risk of BMD loss. These findings suggest preventive measures particularly in patients <50 years.

Use of oral corticosteroids and risk of fractures

Oral corticosteroids and fracture risk: relationship to daily and cumulative doses

Use of inhaled corticosteroids and risk of fractures

Use of oral corticosteroids in the United Kingdom

Children and the risk of fractures caused by oral corticosteroids

The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis

Fracture risk with intermittent high‐dose oral glucocorticoid therapy

Longitudinal study of short-term corticosteroid use by working-age adults with diabetes mellitus: Risks and mitigating factors

Effect of fracture risk in inhaled corticosteroids in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis

Assessment of osteoporosis and fracture risk in people with interstitial lung disease, can we do better?

Corticosteroid Injections and Risk of Fracture

Bone density threshold and other predictors of vertebral fracture in patients receiving oral glucocorticoid therapy

Low-dose glucocorticoid increase the risk of fracture in postmenopausal women with low bone mass: a retrospective cohort study

Use of oral glucocorticoids and risk of cardiovascular and cerebrovascular disease in a population based case–control study

Risk of Fracture and Osteoporosis in Patients With COPD and Inhaled Corticosteroids Treatment

Rheumatoid arthritis, corticosteroid therapy and hip fracture.

The association between inhaled corticosteroid and osteoporosis and fracture

Elevated Fracture Risks in Patients Using Inhaled Corticosteroids: A Korean Nationwide Study

Update on the Treatment of Glucocorticoid-Induced Osteoporosis

Use of statins and risk of fractures

Impact of treatment with inhaled corticosteroids on bone mineral density of patients with asthma: related with age